Non-insulin oral drug(s)-Farxiga (dapagliflozin) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Farxiga (dapagliflozin) Posts on Medivizor

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Posted by on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin...

Read More

Evaluating the safety of dapagliflozin in patients with type 2 diabetes

Evaluating the safety of dapagliflozin in patients with type 2 diabetes

Posted by on Apr 25, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the side effects of dapagliflozin (Farxiga) for patients with type 2 diabetes (T2D). It found that dapagliflozin was well tolerated and led to less kidney injury for patients with T2D. Some background T2D is a disorder that causes high levels of glucose (sugar) in the blood. Over time, high blood glucose can cause a...

Read More

Looking for patients with type 2 diabetes to test a new treatment tirzepatide

Posted by on Feb 27, 2019 in Diabetes mellitus | 0 comments

In a nutshell This trial is examining the effectiveness of tirzepatide compared to insulin glargine in patients with type 2 diabetes who are also at high risk for heart disease. The main outcome to be measured will be a change in HbA1c (a blood test that measures average blood sugar levels in the past 3 months) over 52 weeks. The details In type 2...

Read More

Evaluating the risk of genital infections with SGLT2 inhibitors for Type 2 diabetes

Evaluating the risk of genital infections with SGLT2 inhibitors for Type 2 diabetes

Posted by on Sep 21, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the risk of genital infections in patients with Type 2 diabetes (T2D) treated with SGLT2 (sodium-glucose cotransporter 2) inhibitors. This study concluded that this therapy was associated with a 3-fold higher risk of genital infections in these patients. Some background SGLT2 inhibitors help the kidneys remove...

Read More